Antithrombotic therapy after left atrial appendage closure

References

• Camm A J, Lip GYH, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012;33:2719-47
   PubMedGoogle Scholar
• Meier B, Blaauw Y, Khattab AA, et al. EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion. Europace 2014;16(10):1397-416
   PubMed Web of Science ®Google Scholar
• Holmes DR, Reddy VY, Turi ZG, et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet 2009;374:534-42
   PubMed Web of Science ®Google Scholar
• Reddy VY, Holmes D, Doshi SK, et al. Safety of percutaneous left atrial appendage closure: results from the Watchman Left Atrial Appendage System for Embolic Protection in Patients with AF (PROTECT AF) clinical trial and the Continued Access Registry. Circulation 2011;123:417-24
   PubMed Web of Science ®Google Scholar
• Holmes DR, Kar S, Price MJ, et al. Prospective Randomized Evaluation of the Watchman Left Atrial Appendage Closure Device in Patients With Atrial Fibrillation Versus Long-Term Warfarin Therapy: the PREVAIL Trial. J Am Coll Cardiol 2014;64:1-12
   PubMed Web of Science ®Google Scholar
• Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883-91
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011;364:806-17
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51
   PubMed Web of Science ®Google Scholar
• Viles-Gonzalez JF, Kar S, Douglas P, et al. The clinical impact of incomplete left atrial appendage closure with the Watchman Device in patients with atrial fibrillation: a PROTECT AF (Percutaneous Closure of the Left Atrial Appendage Versus Warfarin Therapy for Prevention of Stroke in Patients Wit. J Am Coll Cardiol 2012;59:923-9
   PubMed Web of Science ®Google Scholar
• Price M, Halperin JL, Reddy V, et al. Bleeding risk and clinical benefit of WATCHMAN left atrial appendage closure in patients eligible for oral anticoagulation: a pooled analysis of the PROTECT-AF and PREVAIL randomized clinical trials. Eur Heart J 2014;35:513-850
   Web of Science ®Google Scholar
• Sievert H. Percutaneous Left Atrial Appendage Transcatheter Occlusion to Prevent Stroke in High-Risk Patients With Atrial Fibrillation: early Clinical Experience. Circulation 2002;105:1887-9
   PubMed Web of Science ®Google Scholar
• Block PC, Burstein S, Casale PN, et al. Percutaneous left atrial appendage occlusion for patients in atrial fibrillation suboptimal for warfarin therapy: 5-year results of the PLAATO (Percutaneous Left Atrial Appendage Transcatheter Occlusion) Study. JACC Cardiovasc Interv 2009;2:594-600
   PubMed Web of Science ®Google Scholar
• Reddy VY, Möbius-Winkler S, Miller MA, et al. Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation: the ASAP study (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology). J Am Coll Cardiol 2013;61:2551-6
   PubMed Web of Science ®Google Scholar
• Windecker S, Kolh P, Alfonso F, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) * Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2014;35(37):2541-619
   PubMed Web of Science ®Google Scholar
• Mant J, Hobbs FDR, Fletcher K, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 2007;370:493-503
   PubMed Web of Science ®Google Scholar
• Ntaios G, Lip GYH, Vemmou A. Koroboki E. long-term stroke outcome in patients without atrial fibrillation. Neurology 2013;80:1009-17
   PubMed Web of Science ®Google Scholar
• Baigent C, Blackwell L, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009;373:1849-60
   PubMed Web of Science ®Google Scholar
• Halvorsen S, Andreotti F, ten Berg JM, et al. Aspirin therapy in primary cardiovascular disease prevention: a position paper of the European Society of Cardiology working group on thrombosis. J Am Coll Cardiol 2014;64:319-27
   PubMed Web of Science ®Google Scholar
• Meier B, Kalesan B, Mattle HP, et al. Percutaneous closure of patent foramen ovale in cryptogenic embolism. N Engl J Med 2013;368:1083-91
   PubMed Web of Science ®Google Scholar
• Registry on WATCHMAN Outcomes in Real-Life Utilization (EWOLUTION). Available from: http://clinicaltrials.gov/show/NCT01972282
   Google Scholar
• Urena M, Rodés-Cabau J, Freixa X, et al. Percutaneous left atrial appendage closure with the AMPLATZER cardiac plug device in patients with nonvalvular atrial fibrillation and contraindications to anticoagulation therapy. J Am Coll Cardiol 2013;62:96-102
   PubMed Web of Science ®Google Scholar
• Santoro G, Meucci F, Stolcova M, et al. Percutaneous left atrial appendage occlusion in patients with non-valvular atrial fibrillation: implantation and up to four years follow-up of the AMPLATZER Cardiac Plug. EuroIntervention 2014; [Epub ahead of print]
   Web of Science ®Google Scholar
• Park J-W, Bethencourt A, Sievert H, et al. Left atrial appendage closure with Amplatzer cardiac plug in atrial fibrillation: initial European experience. Catheter Cardiovasc Interv 2011;77:700-6
   PubMed Web of Science ®Google Scholar
• Meincke F, Schmidt-Salzmann M, Kreidel F, et al. New technical and anticoagulation aspects for left atrial appendage closure using the WATCHMAN® device in patients not taking warfarin. EuroIntervention 2013;9:463-8
   PubMed Web of Science ®Google Scholar
• Chun KRJ, Bordignon S, Urban V, et al. Left atrial appendage closure followed by 6 weeks of antithrombotic therapy: a prospective single-center experience. Heart Rhythm 2013;10:1792-9
   PubMed Web of Science ®Google Scholar
• Miller MA, Gangireddy SR, Doshi SK, et al. Multicenter study on acute and long-term safety and efficacy of percutaneous left atrial appendage closure using an epicardial suture snaring device. Heart Rhythm 2014. [Epub ahead of print]
   Web of Science ®Google Scholar
• Bartus K, Han F, Bednarek J, et al. Percutaneous left atrial appendage suture ligation using the LARIAT device in patients with atrial fibrillation: initial clinical experience. J Am Coll Cardiol 2013;62:108-18
   PubMed Web of Science ®Google Scholar
• Price MJ, Gibson DN, Yakubov SJ, et al. Early Safety and Efficacy of Percutaneous Left Atrial Appendage Suture Ligation: results From the U.S. Transcatheter LAA Ligation Consortium. J Am Coll Cardiol 2014;64:565-72
   PubMed Web of Science ®Google Scholar